Rabin, Alexandra
Bello, Elisa
Kumar, Saurabh
Zeki, Dalia Abou
Afshari, Khashayar
Deshpande, Mugdha
Francis, Nimmy
Khalighinejad, Farnaz
Umeton, Raffaella
Radu, Irina
Qutab, Fatima
Kwong, Danny
Kurban, Mariana
Hemond, Christopher
Richmond, Jillian M.
Ionete, Carolina
Funding for this research was provided by:
2020 Consortium of Multiple Sclerosis Centers (CMSC) Medical Student Research Scholarship
2022 CMSC Medical Student Research Scholarship
2021 CMSC Medical Student Research Scholarship
SPARK grant from the UMass Center for Clinical and Translational Science (grant #UL1-TR001453)
SPARK grant from the UMass Center for Clinical and Translational Science (grant #UL1-TR001453)
Article History
Received: 21 April 2024
Accepted: 12 July 2024
First Online: 18 September 2024
Competing interests
: JMR is an inventor on patent application #15/851,651, “Anti111-human CXCR3 antibodies for the Treatment of Vitiligo” which covers targeting CXCR3 for the treatment of vitiligo; and on patent #62489191, “Diagnosis and Treatment of Vitiligo” which covers targeting IL-15 and Trm for the treatment of vitiligo. The remaining authors declare that the research was conducted in the absence of any competing interests that could be construed as a potential conflict of interest.